

**An International Review of Health Technology Assessment
Drugs and Their Ethical Principles**

Journal of Law, Medicine and Ethics

48, 583-594

DOI: [10.1177/1073110520958885](https://doi.org/10.1177/1073110520958885)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review. Health Affairs, 2021, 40, 1402-1410.	5.2	17
2	QALYs In Health Resource Usage Decisions: The Authors Reply. Health Affairs, 2022, 41, 610-610.	5.2	0
3	Trends in Prescription Drug Launch Prices, 2008-2021. JAMA - Journal of the American Medical Association, 2022, 327, 2145.	7.4	45
4	Assessing U.S. Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies. Journal of Health Politics, Policy and Law, 2022, , .	1.9	2
5	Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries. Pharmacoeconomics, 2022, 40, 1131-1142.	3.3	2
6	Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare. JAMA - Journal of the American Medical Association, 2023, 329, 1283.	7.4	11
7	Gauging the Value of Top-Selling Drugs in Medicare—Reply. JAMA - Journal of the American Medical Association, 2023, 330, 665.	7.4	0
8	Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis. JAMA Dermatology, 2024, 160, 409.	4.1	0